The Rise of Hybrid Trials
Although decentralized trials (DCT) existed prior to the pandemic, COVID-19 undoubtedly had a large impact on the rapid adoption of DCT technologies. As global regulators become more accepting of these novel technologies, patients become accustomed to using them, and DCT enters the mainstream lexicon, it’s important to distinguish how and where it will benefit clinical research the most. This paper defines what a hybrid trial is, how it utilizes decentralized technologies, and the reason for mainstream adoption of hybrid clinical trials.